Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2348-2354

  Mueller, Sarah Kristin ^a   Altvater, Bianca ^a   Chen, Christiane ^a   Kailayangiri, Sareetha ^a   Ahlmann, Martina ^a   Dirksen, Uta ^a   Juergens, Heribert ^a   Rossig, Claudia ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Aminobisphosphonates; Cellular immunotherapy; NK cells

Indexed keywords

BIOLOGICAL MARKER; CD137 LIGAND; CD226 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CYTOCHROME P450 2B4; GLYCOPROTEIN; INTERLEUKIN 15; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL EXPANSION; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DEGRANULATION; DOSE RESPONSE; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION; UPREGULATION;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL DEGRANULATION; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; K562 CELLS; KILLER CELLS, NATURAL; PHENOTYPE; SARCOMA, EWING;

EID: 84876260511     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2350     Document Type: Article

References (37)

1. Potratz J, Dirksen U, Jurgens H and Craft A: Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 29: 1-11, 2012.
2. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 22: 488-493, 1996 (Pubitemid 26067736)
3. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978, 2003. (Pubitemid 36829676)
4. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, et al: Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 70: 7610-7619, 2010.
5. Zhou Z, Guan H, Duan X and Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104: 1713-1720, 2005. (Pubitemid 41437436)
6. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH and Child JA: Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 119: 5374-5383, 2012
7. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini F: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37: 74-86, 2005. (Pubitemid 40848420)
8. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, et al: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11: 421-428, 2010.
9. Zarogoulidis Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I and Karamanos NK: The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125: 1705-1709, 2009.
10. Siddiqui T, Marsh RW, Allegra C, Whittaker D, Scarborough M, Gibbs P, Zlotecki R, Reith JD and Drane W: Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid. Clin Adv Hematol Oncol 8: 499-504, 2010.
11. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A and June CH: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73, 2011.
12. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901-3909, 2010.
13. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N and Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother 58: 699-708, 2009.
14. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H and Wargo JA: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70: 5213-5219, 2010.
15. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R and Bukowski R: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14: 6674-6682, 2008.
16. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A and Odum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65: 11136-11145, 2005. (Pubitemid 41713385)
17. Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP, Egeler RM, Hogendoorn PC and Lankester AC: Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res 2: 8, 2012.
18. + T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 37: 256-265, 2009.
19. Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI and Zwirner NW: Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol 91: 321-331, 2012.
20. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, et al: Effector gamma delta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19: 664-670, 2005. (Pubitemid 40521173)
21. Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg Werth D, Grünebach F and Brossart P: Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 21: 732-738, 2007. (Pubitemid 46444557)
22. Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I and Thiebaud D: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 15: 147-154, 2000. (Pubitemid 30026942)
23. Liote F, Boval-Boizard B, Fritz P and Kuntz D: Lymphocyte subsets in pamidronate-induced lymphopenia. Br J Rheumatol 34: 993-995, 1995.
24. Nussbaumer O, Gruenbacher G, Gander H and Thurnher M: DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Blood 118: 2743-2751, 2011.
25. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, et al: Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51, 2010.
26. Imai C, Iwamoto S and Campana D: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383, 2005. (Pubitemid 40967217)
27. Alter G, Malenfant JM and Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15-22, 2004. (Pubitemid 39626587)
28. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, et al: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228-1236, 2002. (Pubitemid 35205058)
29. + NK-cell subset. Blood 116: 3865-3874, 2010.
30. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102: 1099-1105, 2010.
31. Wang H, Sarikonda G, Puan KJ, Tanaka Y, Feng J, Giner JL, Cao R, Monkkonen J, Oldfield E and Morita CT: Indirect Stimulation of Human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol 187: 5099-5113, 2011.
32. Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens A and Kuball J: Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood 118: 50-59, 2011.
33. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE and Chapoval AI: Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 116: 1726-1733, 2010.
34. Sarhan D, D'Arcy P, Wennerberg E, Liden M, Hu J, Winqvist O, Rolny C and Lundqvist A: Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-gamma. Eur J Immunol: Sep 19, 2012 (Epub ahead of print).
35. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69: 4010-4017, 2009.
36. Dowell AC, Oldham KA, Bhatt RI, Lee SP and Searle PF: Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol Immunother 61: 615-628, 2012.
37. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ, Schilham MW and Lankester AC: NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 45: 3917-3925, 2008.